Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.37 and traded as high as $1.56. Cortexyme shares last traded at $1.54, with a volume of 48,558 shares traded.
Cortexyme Stock Up 4.8 %
The stock has a market cap of $46.43 million, a P/E ratio of -0.52 and a beta of 1.40. The stock has a fifty day simple moving average of $1.62 and a 200-day simple moving average of $1.37.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
See Also
- Five stocks we like better than Cortexyme
- What Are Some of the Best Large-Cap Stocks to Buy?
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- There Are Different Types of Stock To Invest In
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
